The story of the erectile dysfunction drug presents a intricate picture for investors. While the initial launch generated massive gains, the lapse of its intellectual property protection opened the door to generic https://mylittlebookmark.com/story7431604/sildenafil-and-the-pharmaceutical-industry-a-risky-opportunity